Navigation Links
Analysis of calls to IBD clinic predicts emergency visits and hospitalizations, Pitt finds
Date:2/7/2014

PITTSBURGH, Feb. 7, 2014 A comprehensive analysis of patient telephone records at an inflammatory bowel disease (IBD) clinic revealed that 15 percent of patients account for half of all calls to the clinic. Forty-two percent of frequent-caller patients also were seen in the emergency department or hospitalized within the following year.

The results, which can help doctors identify patients with the most severe disease and those at risk of potentially avoidable high-cost medical interventions, were reported in a study published online this week in the journal Clinical Gastroenterology and Hepatology.

Inflammatory bowel diseases (Crohn's disease and ulcerative colitis) are chronic lifelong conditions which affect the gastrointestinal tract of up to 2 million Americans, the majority of whom are diagnosed as young adults. Telephone communication in IBD care is common, and involves reporting clinical status, treatment, reassurance, and completion of health care forms and insurance authorization. Yet, until now, there has been limited information on telephone activity volume or the reasons for calls in the care of chronic illness, including IBD.

"Telephone surveillance and the use of big data allowed us to find red flags identifying patients at risk of high-cost medical interventions, such as emergency department use and/or hospitalization. These findings can help to identify disease severity and teach us how to take better care of our patients," noted senior author David Binion, M.D., visiting professor of medicine, clinical and translational science and co-director of the IBD Center at the University of Pittsburgh School of Medicine.

Researchers tracked more than 50,000 phone calls over a period of two years, from over 3,000 patients. The researchers assessed associations between clinical factors and logged telephone encounters, and between patterns of telephone calls and future visits to the emergency room or hospitaliz
'/>"/>

Contact: Cristina Mestre
mestreca@upmc.edu
412-586-9776
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New analysis finds hempseed oil packed with health-promoting compounds
2. Global In Vitro Diagnostics (IVD) Market 2013
3. Industry Analysis, Size, Share, Growth, Trends and Forecast Research Report Available Online by Researchmoz.us
4. Global Sealant Industry & China Aerogel Market Size Analysis in New Research Reports at DeepResearchReports.com
5. Commercial Airport Lighting Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
6. PhUSE Working Group Active in Developing Standard Analysis Scripts
7. China Digital Radiography Industry & Global CBCT Market Analysis in a New Research Study Available at DeepResearchReports.com
8. Download Merrill DataSite's Report - Monthly M&A Insider: December 2013 - Analysis of a Mixed M&A Picture
9. 2014 Vitamin C and Vitamin A Market China Global Analysis in a New Research Available at Deepresearchreports.com
10. Chemical imaging brings cancer tissue analysis into the digital age
11. GlycoZym Product Analysis and Market Research Report 2013 Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Melbourne, Australia (PRWEB) November 28, 2014 ... has undergone healthy growth over the past five ... population's increasing acceptance of therapies that are either ... conventional treatments. According to IBISWorld industry analyst David ... the ageing population and growing private health insurance ...
(Date:11/28/2014)... Kramer HealthDay Reporter , THURSDAY, ... the kitchen, through cooking classes or at home, may make ... recent review. Cooking programs and classes for children seem ... the new research. And, although the review didn,t look at ... programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... November 28, 2014 Mabel’s Labels ... kids lose® and an award-winning company established by four ... Cynthia Esp, and Tricia Mumby have been honored with ... recognized with the PROFIT Award for Excellence in Entrepreneurship. ... Esp, and Tricia Mumby) accepted the award on behalf ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Patten Pecans, ... locally grown. With those passions driving them, they've added ... Grown. Having tried other pecans oils, they've found this ... Georgia to be exceptionally flavorful, retaining the buttery pecan ... same nutritional benefits found in pecans nuts ...
(Date:11/28/2014)... Brentwood, TN (PRWEB) November 28, 2014 ... in Tennessee for the first time. PAI Medical Group ... M.D. will be performing a robotic hair transplant procedure ... at 9:00 A.M. , The first in Tennessee and ... PAI Medical Group now offers ARTAS robotic hair transplantation. ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2
... from more emotional and behavioral difficulties when compared to ... the most when a parent is deployed overseas, according ... that having a parent deployed for a longer period ... struggled with emotional problems were important factors associated with ...
... , NEW ORLEANS and SUNNYVALE, Calif., Dec. ... interim results from a Phase I/II study showing safety and ... (NHL) treated with its HDAC inhibitor PCI-24781 as a single ... Annual Meeting being held in New Orleans, LA (Abstract # ...
... growth factor, researchers say , SUNDAY, Dec. 6 (HealthDay ... main tumor to other parts of the body is controlled ... a promising target for new drugs to prevent metastatic breast ... TGFb (transforming growth factor beta) regulates normal cell growth and ...
... NEW ORLEANS, Dec. 6 Sickle cell disease, a condition ... of the most common genetic blood disorders affecting millions of ... presented today at the 51st Annual Meeting of the American ... that the H1N1 pandemic presents for children with this blood ...
... ... Greater VA Healthcare System in West Los Angeles, will once again create a holiday party. ... and their families. , ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of the community, in cooperation ...
... 5 , What: Cuts for a Cause ... fight against cancer and other terminal illnesses affecting children. All proceeds ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, ... Falls Church for all guests. Hoa Lai, a DJ known for ...
Cached Medicine News:Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
(Date:11/28/2014)... , Nov. 28, 2014 Alimera Sciences, ... pharmaceutical company that specializes in the research, development ... into a Securities Purchase Agreement with Deerfield Management ... which Alimera will issue shares of preferred stock ... approximately $50.0 million upon the satisfaction of certain ...
(Date:11/27/2014)... CORK, Ireland , November 27, 2014 ... first Investigational New Drug (IND) Application with the U.S. ... milestone in Hovione,s strategy of developing improved drug delivery ... submitted for minocycline gel, a novel formulation using a ... topically one of the most widely prescribed oral antibiotics ...
(Date:11/26/2014)... -- Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it has ... million at a price of $0.30 per unit. The ... Each unit consists of one common share and one ... whole warrant entitles the holder to acquire one common ... of five years from closing.  Roth ...
Breaking Medicine Technology:Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Hovione Files its First Investigational New Drug Application With the FDA 2Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3
... Therapeutics (Nasdaq: NKTR ) today reported its financial ... 2010. Cash, cash equivalents, and short-term investments ... at December 31, 2010 does not include proceeds of $220.4 ... in January 2011.   Revenue for the fourth ...
... 2011 OncoMed Pharmaceuticals, Inc., a company developing novel ... publication of preclinical data demonstrating that its lead candidate, ... frequency when administered alone or in combination with chemotherapy ... mutations.  This study was published in the March 1, ...
Cached Medicine Technology:Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 7OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 2OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 3OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 4OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 5
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
... fixation device offers superior fixation strength ... firmly reattaches soft tissue to the ... is indicated for the fixation of ... bone. The implant is composed of ...
... simple to use system can be used ... and is pre-packaged on a sterile disposable ... a simple and reproducible insertion of the ... Sliding (I.S.S.™) Eyelet Design allows for the ...
... is the smallest, strongest anchor on ... placement into even the smallest bones. ... or 4-0 ETHIBOND EXCEL suture with ... swaged needles. The kit includes a ...
Medicine Products: